Optimizing Single-cell Dispensing for Microbial Research
Date: June 2, 2021
Time: 4:30pm AEST
Description: A fully anaerobic cultivation workflow for high-throughput isolation of gut bacteria
Automated and label-free cloning of coli and yeast. Genome sequencing of uncultivated bacteria in the human oral microbiome. Using the B.SIGHT™ single-cell dispenser for automated and label-free isolation of bacteria, archaea and yeast
Deep Dive: Luminex Multiplex Assays
Date: Wednesday 19th May.
Time: 2.00pm AEST & 12.00pm NZ.
Description: Multiplexing is key for screening various biomarkers for the identification of diseases. During this webinar Senior Bio-Techne Scientist, Richard Fuerstenburg, will walk you through the validation needed for Luminex assays. You’ll also learn about the factors that provide specificity and sensitivity to our Bio-Techne assays.
"Why active diffusion and low shear forces makes a difference when cultivating cells in 3D”
Join us for the first webinar from CelVivo, titled, “Why active diffusion and low shear forces makes a difference when cultivating cells in 3D”
Date: Tuesday 22nd of April 4PM AEST.
Please Register in advance for this webinar
Please send your Questions in advance to firstname.lastname@example.org and they will be answered during the session.
When: 8th April 2021
2pm AEST Australia
4pm New Zealand
• Nithya Jesuraj, Ph.D. (Product Manager, Genome Engineering, Bio-Techne)
• Kevin Flynn Ph.D. (R&D Manager, Stem Cells, Bio-Techne)
IN VITRO TECHNOLOGIES and BIO-TECHNE IS DELIGHTED TO INVITE YOU TO ATTEND OUR LIVE WEBINAR.
We are bringing together Bio-Techne experts across disciplines within Cell and Gene Therapy to present and explore:
We are excited to provide this forum to discuss these key topics with 2 key speakers and a Q&A/Panel session.
Friday 26 March , 2021
12:00 noon - 1 PM AEST
10:00-11:00 AM New Zealand
Discover ATCC’s range of differentiated iPSCs cells for toxicology & cancer research.
Toxicology and cancer researchers alike are challenged by the lack of a consistent source of cells with high physiological relevance for their cell-based assays. The source tissue for primary cells comes from a variety of donors, which can introduce interexperimental variability and confound experimental results. Differentiated induced pluripotent stem cell (iPSC)-derived cells fulfill the need for a consistent source of cells and physiological relevance. iPSCs are able to be generated in large cell numbers from a single clone, providing the needed consistency. Further, iPSCs can be differentiated into a variety of desired, functional cell types, affording the necessary biological relevance. Here we provide data demonstrating how differentiated iPSC-derived cells can be incorporated into immunoassays or further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.
Brian Shapiro, PhD, Scientific Content Specialist, ATCC
Brian A Shapiro, Ph.D., works to communicate the scientific breakthroughs of ATCC’s product development laboratories to the biomedical research community. Previously, he worked at Virginia Commonwealth University, where he investigated the role of pre-mRNA splicing in the multi-drug resistance of lung cancer. Dr. Shapiro attended the Medical College of Georgia, where his research focused on adrenal physiology as well as diseases of the epidermis.
Join Advanced Cell Diagnostics & In Vitro Technology for this exciting Nature Research (Publishing) webinar on
When: Wed March 17, 2021
Time: 12PM AEST
Speaker: Ankur Sharma, Ph.D., Harry Perkins Institute of Medical Research and Curtin University, Perth, Australia
This webcast will describe employing single cell genomics and spatial transcriptomics to discover a previously unexplored oncofetal reprogramming of the tumor ecosystem.
Analysis of ~212,000 cells representing human fetal, hepatocellular carcinoma (HCC), and mouse liver revealed remarkable fetal-like reprogramming of the tumor microenvironment. Specifically, the HCC ecosystem displayed features reminiscent of fetal development, including re-emergence of fetal-associated endothelial cells and fetal-like tumor-associated macrophages.
The speaker will describe a shared immunosuppressive oncofetal ecosystem in fetal liver and HCC and its potential implications for targeting therapeutic interventions in HCC and identifying similar paradigms in other cancers and diseases.
You will learn:
• Identification of fetal-associated endothelial cells and macrophages in HCC
• Shared oncofetal ecosystem between human fetal liver and HCC
• The phenomenon of oncofetal reprogramming in the tumor ecosystem
Friday, February 26, 2021
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives. The ISCT ANZ 2021 Virtual Regional meeting is scheduled for 26th of February 2021. In Vitro Technologies are proud to support this event as a sponsor and will have a virtual booth to exhibit our Cell and Gene Therapy (CGT) portfolio. The team at In Vitro Technologies can help you at all stages of CGT Research: from discovery to the clinic. Our high quality reagents and consumables will help ensure confidence in your data, while our closed-automation equipment will help achieve critical challenges: scalability and manufacturability. Register Now! .
December 15-16th, 2020
This conference brings together the necessary ingredients to create a meaningful immunotherapeutic platform to attack cancer and step down the path to potentially cure it. The 2020 Eradicate Cancer will be a virtual conference (15-16th December 2020) There will be an outstanding faculty of speakers at Eradicate Cancer 2020. Register Now! .
Wednesday, October 21st, 2020 11.00AM In Paris.
Among challenges in bioprocessing, cell counting is one of the most critical. Standardization of the cell counting method to assess cell concentration and viability requires careful selection. Choice of the method, accuracy and precision of the devices, throughput and compliance are some of the factors which can impact the success of cell production.
Wednesday, October 21st, 2020 from 14.00 - 14.30 AEDT.
High quality milk products can only be produced from high quality raw milk, so a close quality control along the milk processing chain is vital - from the intake at the dairy plant, to the various processing steps, and the end products. This live webinar allows you to learn about the latest near infrared spectroscopy (NIR) technology, how to make use of it to improve food quality, safety and process control monitoring.
Ms. Nattakarn Navasearttavisootr
Visualize ASO, miRNA and siRNA Detections with Spatial Resolution
Tuesday, September 22nd 2020
11:00 A.M to 12,30PM. Australian Eastern Standard Time
Monday, August 26th, 2020
1:00 P.M. Australian Eastern Standard Time
Coronavirus research is picking up pace across the world but due to social distancing measures tools that provide accurate results in minimum hand on time are the need of the hour. Bio-Techne has developed many tools to help researchers study and fight the virus that will be coverd today. This symposium is divided into four talks, beginning with a discussion on COVID-19 related proteins in the first session followed by antibodies, analytical tools for serology and small molecules and ISH assay.
Anthony Person, Senior Director, Proteins at Bio-Techne
Steve Orstad, Antibodies at Bio-Techne
Annegret Boge Product Manager Bio-Techne
Suruchi Arora Product Manager Bio-Techne
Friday, June 5, 2020
1:00 A.M. Australian Eastern Standard Time
3:00 A.M. New Zealand
Also available on Demand
Join us for this timely panel discussion that will cover ongoing research and clinical trials to manage acute respiratory distress syndrome (ARDS) in COVID-19 patients. Two experts will share their extensive experience with therapies using mesenchymal stem cells (MSCs) and the small extracellular vesicles (sEVs) that MSCs produce as potential treatments for COVID-19 patients with ARDS. Jim Beltzer, PhD, from Terumo BCT will facilitate the discussion.11:00 a.m. Eastern Time, USA
In this webinar, we will:
Explore how small extracellular vesicles can recapitulate the therapeutic effect of MSCs
Discuss clinical trial design with critically ill patients (such as those with COVID-19), including strategies for optimizing sample size, managing patient and disease heterogeneity, and maximizing the use of trial data
Learn how the lung inflammatory environment may alter mesenchymal stem cell behaviour
Ben Buller, PhD, Associate Scientist, Henry Ford Health System
Michael Matthay, MD, Professor of Medicine, University of California San Francisco
Jim Beltzer, PhD, Senior Manager, Terumo BCT
Thursday, April 30, 2020
11:00 A.M. Australian Eastern Standard Time
1:00 P.M. New Zealand
This webinar will benefit both new and experienced RNAscope® technology users.
Amrita Roy, PhD
Field Application Scientist
Advanced Cell Diagnostics, Bio-Techne
Thursday, April 23, 2020
11:00 A.M. Australian Eastern Standard Time
1:00 P.M. New Zealand
Vaccines against viral infections like polio, chickenpox, measles, and viral hepatitis are manufactured by producing large quantities of viral particles in a scaled-up tissue culture system. A handful of historical cell lines like Vero (green monkey kidney) and MDCK (canine kidney) are approved by the FDA for viral vaccine production. However, other than clone selection and substrate adaption, relatively little has been done to improve the inherent viral production capacity of the cell lines. ATCC used CRISPR/Cas9 gene editing to create improved versions of cell lines commonly used for viral vaccine manufacturing. These cells produce model
clinical viruses at titers 10-fold higher than the corresponding parental cell line, which has the potential to significantly reduce costs associated with virus and viral vaccine production.
In this webinar, ATCC Scientist Dr. Liz Gillies will cover these key takeaways:
Liz Gillies, Ph.D., Scientist, ATCC
In this webinar, Dr. David Ferrick discusses how advances in our understanding of T cell co-receptors have led to new strategies for keeping immune cells turned on in the suppressive, hostile tumor microenvironment. Much has been learned in the last decade about metabolic reprogramming in cancer, focused initially on tumor metabolism. However, by applying this knowledge to infiltrating immune cells we are now beginning to appreciate the metabolic drivers of immune cell fitness, specifically stable mitochondrial function that can perhaps reverse exhaustion phenotypes by enhancing survival and function in hypoxic and nutritionally depleted tumor microenvironments.
David Ferrick, Ph.D,
Senior Strategy Director
Cell Analysis, Agilent
The aberrant accumulation of regulatory T cells (Tregs) in tumors promotes immunosuppressive features of the tumor microenvironment (TME). Although depleting Tregs unleashes antitumor immunity and reprograms the immune status of the TME, the therapeutic potential of Treg-targeting is largely compromised due to autoimmunity induced by systemic loss of Tregs. Given that Tregs reside in different locations where they contain distinct nutrient composition, metabolic adaptation should be engaged by Tregs to support their tissue retention and tissue-dependent behavior. This talk discusses how we can selectively demolish intramural Tregs by targeting unique metabolic preference of intratumoral Tregs and how this approach can be utilized for cancer research.
Ping-Chih Ho, Ph.D,
Department of Fundamental Oncology,
University of Lausanne Ludwig Center for Cancer Research.
Adoptive cell therapies have come of age, establishing living cells as a powerful therapeutic modality in terms of specificity, durability and adaptability. Agilent Seahorse technology is enabling the shift to real-time quantification of immune cell function, opening a new window on controlling immune cell fate and outcomes. Several translational research studies have demonstrated that altering metabolic behavior can direct immune responses and outcomes. Move beyond analyzing what your cells are, and reveal a clearer picture of what they do in order to harness their therapeutic potential.
David Ferrick, Ph.D
Cell Analysis Division - Agilent Technologies
Over the past few decades, much has been written about misidentification of cell lines, primarily human cell lines. It is not unusual that studies of the ‘same’ cell lines performed by different laboratories often show different results using the same methodology. Hear Dr. Shapiro discuss the implementation of best tissue culture practices to include routine authentication of human cell lines by short tandem repeat (STR) profiling.
Brian Shapiro, Ph.D. Technical Writer, ATCC
Employing good aseptic technique and understanding the specific culture requirements of a strain are essential for optimal viral growth. In this webinar, we will discuss the basic principles for propagating animal viruses in the laboratory. Here, we will highlight best practices for making good virus stocks with an emphasis on the art and science of virus culture that should be followed to help avoid contamination and cross-contamination. Further, we will provide an in-depth look at viral culturing practices in both cell culture and embryonated chicken eggs using Influenza virus as an example.
Metabolism is critical for normal macrophage function - upon activation there is a dramatic metabolic switch towards glycolysis. In this webinar we will discuss new approaches for quantifying macrophage activation in real time using an Agilent XF analyzer.
Brian Dranka, Ph.D.
Biology Manager, Seahorse XF Products, Agilent Technologies, Inc.
The recent development of the CRISPR/Cas9 system provides a revolutionary gene-editing technology. It is not only an advanced tool for basic research in biology but also a breakthrough technique for the development of targeted cancer therapies.
Fang Tian, Ph.D., Lead Scientist, ATCC Cell Systems
Lysa-Anne Volpe, M.S., Senior Biologist, ATCC Cell Systems
Macrophages undergo profound metabolic changes when they are being activated. A major event is a switch to glycolysis which occurs in response to the bacterial product LPS.
Luke O’Neill PhD FRS
Professor of Biochemistry, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin
Assessing cell viability and cell health is crucial to all aspects of cell culture. In addition to the proper maintenance of cell stocks, cell health practices increase the level of confidence in experimental results.
Steven Budd, M.S., MBA Product Line Business Specialist, ATCC Cell Systems
Duojiao Wu, M.D., Ph.D. - Associate Professor in Zhongshan Hospital, Fudan University, Principle Investigator and Director of Systems Immunology. Group/Platform in Shanghai Institute of Clinical Bioinformatics
This webinar will explore the intricate links between immunology and metabolism.
Lydia Lynch - Associate Professor. Trinity College Dublin Instructor, Harvard Medical School
Christoph Hess - Professor of Medicine. University Hospital Basel
Nicholas Restifo - Senior Investigator. National Cancer Institute
Moderator: Anne Granger - Scientific Editor, Cell Metabolism
Learn why metabolism is important – think beyond cellular energetics and how metabolism changes in different stem cell populations (eSCs, iPSCs and adult SCs).
Dr. James Ryall
Department of Physiology
The University of Melbourne
In Vitro Technologies are proud to invite Dr Yuling Luo, President of Advanced Cell Diagnostics to present a seminar series on Next Generation RNA In Situ Hybridization Technologies For Research and Diagnostics.
Dr Yuling Luo
President of Advanced Cell Diagnostics
Join us on Thursday, May 18 to hear Ms. Carol Horton discuss the best practices for stock maintenance with regard to passage, storage, recovery, and microbial authentication, and how ATCC manages these through the seed stock concept, adhering to the specific needs of each culture, and polyphasic strain authentication.
Carol Horton, M.S.
Marketing Manager, ATCC
Getting good conclusive results from your experiments begins with accurate analysis of your data. In this webinar, we will focus on the RNAscope® Assay and the following topics:
Dr. Nancy Ciau
Board Certified Pathologist,
Advanced Cell Diagnostics, Inc.
Please join us for our webinar on Next Generation Targets for Immuno-Oncology. This webinar will discuss novel immunoregulatory pathways that we have uncovered as potential targets for oncology research and cancer immunotherapy.
Anthony Person, PhD
Manager in Bioassay Development
Mycoplasma infection can deprive host cells of nutrients and induce global changes in host gene expression, which in turn can affect data reproducibility and lead to the misinterpretation of experimental results. Best practices in cell culture coupled with routine testing is critical for the prevention and early detection of mycoplasma contamination.
Thursday, September 20, 2018
2:00 am Tuesday, in Sydney NSW
Reed Shabman, Ph.D.,
Lead Scientist, ATCC Standards Resources Center
Balsam Shawky, M.S.,
Senior Biologist, ATCC Standards Resource Center
In this webinar we will discuss:
- How CAR-T cells containing 4-1BB signaling domains have enforced in vitro persistence
- 4-1BB-enforced metabolic reprogramming enhances oxidative metabolism
- Mitochondrial biogenesis is selectively induced in 4-1BB CAR-T cells.
Roddy O'Connor, PhD
University of Pennsylvania
Center for Cellular Immunotherapies
This webinar will discuss how merging quantitative, rate-based measurements of oxygen consumption with detailed pathway analysis using mass spectrometry have revealed the mitochondrial pyruvate carrier (MPC) as a central regulator of metabolic flexibility.
Ajit Divakaruni - Assistant Professor, Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA)
Get the most out of your RNAscope® Multiplex Fluorescent assays
RNAscope® Multiplex Fluorescent assays are ideal for single-molecule detection of multiple RNA targets simultaneously within the same tissue. They are very powerful in identifying co-expression or co-localization of RNA within specific sub-populations of cells.
Mutations in mitochondrial DNA (mtDNA) cause diseases typically affecting the nervous system and for which no effective treatment exists.
Alessandro Prigione, M.D, Ph.D.
Independent Team Leader
Max Delbrueck Center for Molecular Medicine (MDC) in Berlin
In vivo studies have shown that kidney membrane transporters play a key part in drug disposition and renal clearance. Primary renal proximal tubule epithelial cells (RPTEC) are the most physiologically relevant cell models, but lose OAT1 and OCT2 transporter expression in culture.
Chaozhong Zou, Ph.D.
ATCC Cell Systems
RNAscope® Technology is a novel in situ hybridization (ISH) assay for detection of target RNA within intact cells. It represents a major advancement in RNA ISH approaches.
In this webinar we will discuss the benefits of both RNAscope® and BaseScope™ assays and share tips and tricks on how to perform these assays successfully to obtain publication-quality RNA in situ results.
This webinar will benefit both new and experienced RNAscope® technology users.
Nidhi Vashistha, Ph.D
Technical Support Scientist
Advanced Cell Diagnostics, Inc
Optimized cell lines are essential for modelling neurodegenerative diseases, screening novel therapeutics, and testing the neurotoxicity of environmental compounds. Neural progenitor cells (NPCs) derived from induced pluripotent stem cells are excellent in vitro models as they can be induced to differentiate down all three neural lineages.
Brian Shapiro, Ph.D.
Technical Writer, ATCC
As pluripotent stem cells become specified towards a neural stem/progenitor cell and then further differentiate into a mature neural cell type, they go through a number of molecular and metabolic changes that shift the balance between glycolysis and oxidative phosphorylation. Through the differentiation process stem cells turn off their dependence on glycolysis and move towards oxidative phosphorylation. However, whether the lineage specific gene expression drives the metabolic switch or vice versa remains unknown and is an aspect the we will further explore in this webinar.
Eva Szabo MSc, PhD
Canada Research Chair in Metabolism in Human Stem Cells and Cancer Development
Principal Investigator - Stem Cell and Cancer Research Institute (SCC-RI)
Assistant Professor - Biochemistry and Biomedical Sciences and Department of Medicine
Michael G. DeGroote School of Medicine
Cells utilize networks that span both temporal and spatial organizations, encompassing many individual steps of regulation. While the regulatory regimes to build networks in synthetic biology has grown from solely transcription to also include protein or RNA modalities, circuits comprised solely of protein-protein interactions have yet to be produced.
Deepak Mishra, Sc.D.
In this webinar we will discuss:
Brian Dranka, Ph.D.
Biology Manager, Seahorse XF Products
Agilent Technologies, Inc.
Recent work has emphasized the importance of metabolic states and energy balance in maintaining stem cell function. Studies at the interface of stem cell biology and metabolism have investigated how metabolic flux is linked to changes in cell fate and dysfunction and have highlighted potential strategies to restore or manipulate stem cell metabolism for therapeutic gains in aging and disease.
In this Cell Press webinar, Alessandro Prigione (MDC), Heather Christofk (UCLA), and Michael Teitell (UCLA) will discuss their work studying metabolic regulation of pluripotency and reprogramming, and provide insights into how cellular metabolism controls self-renewal, differentiation, and survival of human pluripotent stem cells
Independent Team Leader
Associate Professor, Biological Chemistry, Molecular & Medical Pharmacology
Professor, Latta Endowed Chair and Chief of the Division of Pediatric and Neonatal Pathology
Scientific Editor, Cell Stem Cell
David Ferrick, PhD
Senior Director Marketing
Cell Analysis Division, Agilent